Isocarboxazid — Membership Pricing

Other medications in Mental Health

• Levomilnacipran
• Lisdexamfetamine
• Lithium
• Lithium Carbonate
• Lorazepam
• Loxapine
• Lumateperone
• Lurasidone

About Isocarboxazid

Isocarboxazid (Marplan) is an older but effective medication used to treat severe forms of depression, especially when other treatments haven't worked. As a monoamine oxidase inhibitor (MAOI), it requires careful management but can offer significant relief. TheDrugClub is dedicated to helping members access essential medications like isocarboxazid at more affordable prices.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Isocarboxazid is approved for (FDA label)

Marplan is indicated for the treatment of depression. Because of its potentially serious side effects, Marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patients. The efficacy of Marplan in the treatment of depression was established in 6-week controlled trials of depressed outpatients. These patients had symptoms that corresponded to the DSM-IV category of major depressive disorder; however, they often also had signs and symptoms of anxiety (anxious mood, panic, and/or phobic symptoms) ( see CLINICAL PHARMACOLOGY ).

Source: Read the full FDA label on DailyMed. Label effective date: April 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Isocarboxazid (FDA label)

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.

Source: FDA prescribing information (DailyMed). Set ID: 95fde749-44ad-4668-86c4-0ff17bca0074. SPL document ID: 97745d9b-c2a6-45e3-9e1e-7fabec4681fb. Label effective date: April 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Isocarboxazid (FDA label)

Adverse Findings Observed in Short-Term, Placebo-Controlled Trials Systematically collected data are available from only 86 patients exposed to Marplan, of whom only 52 received doses of ≥50 mg/day, including only 11 who were dosed at ≥60 mg/day. Because of the limited experience with systematically monitored patients receiving Marplan at the higher end of the currently recommended dose range of up to 60 mg/day, caution is indicated in patients for whom a dose of 40 mg/day is exceeded ( see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 95fde749-44ad-4668-86c4-0ff17bca0074. SPL document ID: 97745d9b-c2a6-45e3-9e1e-7fabec4681fb. Label effective date: April 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Isocarboxazid (FDA label)

Marplan (isocarboxazid) should not be administered in combination with any of the following: MAO inhibitors or dibenzazepine derivatives; sympathomimetics (including amphetamines); some central nervous system depressants (including narcotics and alcohol); antihypertensive, diuretic, antihistaminic, sedative or anesthetic drugs, buproprion HCL, buspirone HCL, dextromethorphan, cheese or other foods with a high tyramine content; or excessive quantities of caffeine. Marplan (isocarboxazid) should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease, hypertension, or history of headache. Contraindicated Patient Populations Hypersensitivity Marplan should not be used in patients with known hypersensitivity to isocarboxazid. Cerebrovascular Disorders Marplan should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease or hypertension. Pheochromocytoma Marplan should not be used in the presence of pheochromocytoma, as such tumors secrete pressor substances whose metabolism may be inhibited by Marplan.

Source: FDA prescribing information (DailyMed). Set ID: 95fde749-44ad-4668-86c4-0ff17bca0074. SPL document ID: 97745d9b-c2a6-45e3-9e1e-7fabec4681fb. Label effective date: April 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Isocarboxazid (FDA label)

See CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS sections for information on drug interactions. Marplan should be administered with caution to patients receiving Antabuse ® (disulfiram, Wyeth-Ayerst Laboratories). In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death. Concomitant use of Marplan and other psychotropic agents is generally not recommended because of possible potentiating effects. This is especially true in patients who may subject themselves to an overdosage of drugs. If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used. The monoamine oxidase inhibitory effects of Marplan may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Marplan.

Source: FDA prescribing information (DailyMed). Set ID: 95fde749-44ad-4668-86c4-0ff17bca0074. SPL document ID: 97745d9b-c2a6-45e3-9e1e-7fabec4681fb. Label effective date: April 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.